Mibolerone (Cheque Drops)

Mibolerone, marketed as Cheque Drops, is an androgenic steroid that was developed specifically for preventing estrus (heat) in female dogs. As a 19-nortestosterone derivative, mibolerone possesses potent androgenic properties that suppress the reproductive hormones responsible for triggering estrus. While the product was FDA-approved for canine use and represented an important option for estrus prevention in breeding and show dogs, Cheque Drops has been discontinued by its manufacturer and is no longer commercially available in most markets. This information is provided for educational purposes and for veterinarians who may encounter dogs with historical exposure to this medication.

The mechanism of action of mibolerone involves suppression of the hypothalamic-pituitary-gonadal axis through its androgenic effects. By providing continuous androgenic stimulation, mibolerone inhibits the release of gonadotropin-releasing hormone from the hypothalamus and subsequently reduces the pituitary secretion of luteinizing hormone and follicle-stimulating hormone. Without these gonadotropins, the normal hormonal cascade leading to estrus cannot occur, and the female dog remains in a state of reproductive quiescence. This mechanism differs from progestin-based estrus suppression and allows prevention of heat cycles without the same pattern of side effects associated with progestin therapy.

Mibolerone was formulated as an oral liquid designed to be administered daily as drops directly into the dog's mouth or mixed with food. The medication required consistent daily administration for effective estrus suppression, and treatment needed to begin during anestrus, before any signs of proestrus appeared. The daily dosing requirement represented a commitment from owners and distinguished mibolerone from depot injectable hormonal products that provided prolonged effects from single administrations. The drug was typically initiated at least 30 days before the anticipated estrus and was approved for use up to 24 months.

The safety profile of mibolerone in dogs requires careful consideration due to the androgenic nature of the compound. Side effects related to androgenic activity include clitoral enlargement, vulvar discharge, behavioral changes, and potential masculinization with prolonged use. Hepatotoxicity was another significant concern, requiring monitoring of liver function during treatment. Because of these significant side effects and the controlled substance status of the drug, mibolerone was reserved for situations where estrus prevention was important enough to warrant acceptance of these risks, such as management of valuable show or breeding dogs. Surgical spaying remained the preferred permanent solution for dogs not intended for breeding.

The primary and approved indication for mibolerone in dogs was the prevention of estrus in adult female dogs that had previously experienced at least one estrous cycle. The drug was specifically indicated for temporary prevention of heat cycles in dogs intended for future breeding or for dogs required to remain intact for show or competition purposes. Mibolerone offered an alternative to surgical spaying for owners who needed to prevent estrus while preserving the dog's future reproductive potential. The approved duration of treatment was up to 24 months, after which the drug was to be discontinued to allow return of normal reproductive cycling.

Show dog management represented one of the primary applications for mibolerone during its commercial availability. Many breed shows and competitions require that dogs remain reproductively intact, yet the timing of estrus cycles could interfere with show schedules or create management challenges during competition events. Mibolerone allowed owners and handlers to prevent estrus during active show careers while maintaining the option for future breeding. The ability to reliably prevent heat cycles without permanent alteration made the drug valuable for this population despite its side effects.

Breeding program management was another important application for mibolerone. Breeders with multiple intact females sometimes faced challenges managing estrus cycles, and the ability to suppress heat in selected animals allowed for better planning and timing of breeding activities. Temporary suppression of estrus in young females not yet ready for breeding or in females being rested between litters provided management flexibility. However, the requirement for daily dosing and the potential for side effects meant that mibolerone use required commitment and careful monitoring.

Mibolerone was not indicated for use in dogs that had never experienced estrus, as the drug's efficacy in prepubertal animals was not established. The medication was also not appropriate for dogs in proestrus or estrus, as treatment initiation during active cycling was not effective. Dogs intended for imminent breeding could not be on mibolerone, as the drug needed to be discontinued and normal cycling allowed to resume before breeding attempts. These limitations meant that mibolerone required careful planning and could not be used as an emergency solution for unexpected estrus.

The selection of mibolerone over other estrus prevention methods depended on the specific circumstances of each case. Compared to progestin-based estrus suppression, mibolerone offered a different side effect profile that some veterinarians and owners preferred for certain patients. The daily oral dosing allowed for more immediate cessation of treatment compared to depot injectable hormones. However, the controlled substance status, potential for androgenic side effects, and requirement for daily compliance made mibolerone appropriate only for well-selected cases where these factors were acceptable.

The administration of mibolerone required strict adherence to dosing guidelines based on the dog's body weight, with daily oral administration being essential for effective estrus suppression. The medication was supplied as an oral liquid with a calibrated dropper for accurate dosing. Dose ranges were established based on body weight categories, with smaller dogs receiving fewer drops and larger dogs requiring more. Precise adherence to the weight-based dosing chart was critical, as underdosing could result in breakthrough estrus while overdosing increased the risk of side effects.

Typical dosing for mibolerone was established as follows: dogs up to 12 pounds received approximately 30 micrograms daily, dogs between 12 and 25 pounds received 60 micrograms daily, dogs between 25 and 50 pounds received 120 micrograms daily, dogs between 50 and 100 pounds received 180 micrograms daily, and dogs over 100 pounds received 180 micrograms or more as directed. German Shepherds and German Shepherd mixes required higher doses due to apparently more rapid metabolism of the drug, typically receiving doses at the next higher weight category. These dosing requirements emphasized the need for accurate weight measurement and careful dose calculation.

Treatment with mibolerone was required to begin during anestrus, at least 30 days before the anticipated onset of proestrus. Initiation of treatment once proestrus signs appeared was not effective and could not prevent the ongoing estrous cycle. This requirement meant that owners needed to track their dog's reproductive cycles and plan treatment initiation accordingly. The 30-day lead time allowed for adequate suppression of the gonadotropin axis before the hormonal changes leading to estrus would otherwise begin.

The medication was administered once daily, preferably at the same time each day to maintain consistent blood levels. The liquid drops could be administered directly into the mouth or mixed with a small amount of food to ensure consumption. Consistent daily administration was absolutely critical, as missed doses could result in breakthrough proestrus or estrus. If a dose was missed, it should be given as soon as remembered, but doses should not be doubled. Multiple missed doses could result in treatment failure and the onset of estrus.

The approved duration of mibolerone treatment was up to 24 months of continuous daily administration. Following this period, treatment was to be discontinued to allow assessment of the dog's reproductive function and to minimize cumulative side effects from prolonged androgenic exposure. When treatment was discontinued, estrus typically resumed within 7 to 200 days, with considerable individual variation in the timing of return to cycling. Dogs could be bred following the first estrus after discontinuation, though some veterinarians recommended allowing one or more cycles before breeding.

Completion of treatment as prescribed was important for achieving the desired estrus suppression, though the decision to continue or discontinue treatment at any point was made in consultation with the veterinarian based on the individual case circumstances. Regular veterinary monitoring during treatment was recommended to assess for side effects, particularly liver function, and to evaluate whether continued treatment was appropriate. The controlled substance status of mibolerone required appropriate prescribing and dispensing records.

Mibolerone was associated with significant side effects related to its androgenic activity, and these effects were important considerations in the decision to use this medication. Unlike many drugs where side effects are uncommon, the androgenic effects of mibolerone were frequently observed with regular use and required acceptance by owners as part of the treatment. Understanding these effects and monitoring for problematic manifestations was essential for safe use of the drug.

The most common androgenic side effects of mibolerone included clitoral hypertrophy (enlargement of the clitoris), vulvar discharge, and changes in vaginal mucosa. These effects were directly related to the androgenic activity of the drug and occurred with some frequency in treated dogs. Clitoral enlargement could be pronounced in some cases and was generally reversible after drug discontinuation, though the time to resolution varied. Vulvar discharge, which could range from clear to mucopurulent in character, occurred in a notable percentage of treated dogs and could sometimes be confused with signs of reproductive tract disease.

Behavioral changes related to androgenic exposure could occur with mibolerone treatment. Some dogs developed increased aggression, territorial behavior, or mounting behavior typically associated with male dogs. Changes in urination patterns, including lifting the leg to urinate or increased marking behavior, were reported in some treated females. These behavioral effects could be problematic depending on the dog's living situation and the owner's tolerance for such changes. Behavioral modifications did not always fully resolve after drug discontinuation.

Hepatotoxicity was a significant concern with mibolerone use, and liver function monitoring was recommended during treatment. The androgenic steroid class of compounds is known to affect liver function, and elevations in liver enzymes could occur with mibolerone therapy. Clinical signs of liver disease, including jaundice, decreased appetite, vomiting, and lethargy, warranted immediate discontinuation of treatment and veterinary evaluation. Baseline liver function testing before treatment initiation and periodic monitoring during treatment helped identify developing hepatotoxicity.

Additional side effects that could occur with mibolerone included body odor changes, increased oiliness of the skin and coat, epiphora (excessive tearing), and various other androgenic effects. Some effects were dose-related and could be minimized with precise dosing, while others occurred even at appropriate doses. The severity of side effects varied considerably between individual dogs, with some showing minimal effects while others developed significant manifestations. Regular veterinary assessment during treatment allowed for ongoing risk-benefit evaluation and timely identification of dogs for whom continued treatment was inadvisable.

Mibolerone was contraindicated in dogs with preexisting liver disease or elevated liver enzymes, given the hepatotoxic potential of androgenic steroids. Baseline liver function testing was recommended before treatment initiation, and dogs with abnormal results should not have received mibolerone. The drug was also contraindicated in dogs with a history of hepatotoxicity from any cause, as the additional hepatic stress from mibolerone could precipitate serious liver damage. Ongoing monitoring of liver function during treatment was standard practice.

The use of mibolerone was contraindicated in pregnant dogs due to the potential for masculinization of female fetuses and other developmental effects from androgenic exposure during gestation. The drug should not have been administered to any dog with possible pregnancy, and pregnancy should have been ruled out before treatment initiation in any dog with recent breeding history. Similarly, mibolerone was contraindicated in lactating dogs due to potential passage of the drug or its effects to nursing puppies.

Mibolerone was not indicated for use in prepubertal female dogs that had not yet experienced their first estrous cycle. The efficacy of the drug in dogs that had never cycled was not established, and use in this population was not recommended. Additionally, dogs with existing reproductive tract disease, including pyometra or other uterine abnormalities, were not appropriate candidates for mibolerone treatment. Perianal gland disorders, which are influenced by androgens, represented another contraindication due to the potential for androgenic stimulation to worsen these conditions.

Certain breed-specific contraindications applied to mibolerone use. Bedlington Terriers, which have a hereditary predisposition to copper-associated hepatopathy, were specifically contraindicated for mibolerone treatment due to heightened hepatotoxicity risk. Other breeds with known liver disease predispositions required careful evaluation before treatment consideration. Any dog with a history of adverse reaction to mibolerone or related androgenic compounds should not have received the drug. Complete health assessment and disclosure of all medical conditions to the veterinarian was essential before treatment.

Complete disclosure of all medications, supplements, and treatments the dog was receiving was essential before initiating mibolerone therapy. As an androgenic steroid, mibolerone had the potential to interact with other hormonal medications and with drugs metabolized through similar hepatic pathways. The veterinarian needed comprehensive medication information to evaluate potential interactions and ensure safe treatment planning.

The most significant potential interactions involved other hormonal medications or anabolic steroids. Concurrent use of other androgens, progestins, or estrogens could result in complex and unpredictable hormonal effects. The combination of multiple hormonal agents was generally not recommended without specific veterinary justification and close monitoring. Corticosteroids, which affect liver function and metabolic processes, could potentially interact with mibolerone's hepatic effects, though specific interaction data in dogs was limited.

Medications metabolized by hepatic enzyme systems could potentially interact with mibolerone or be affected by mibolerone-induced changes in liver function. Dogs receiving medications requiring hepatic metabolism should have been monitored carefully if mibolerone was used concurrently. Drugs with known hepatotoxic potential required particular caution, as combined hepatic stress could increase the risk of liver damage. The veterinarian evaluated all concurrent medications for potential hepatic concerns before and during mibolerone treatment.

Supplements and nutraceuticals with hormonal activity or effects on liver function should have been disclosed to the veterinarian managing mibolerone therapy. Herbal products with purported hormonal effects could potentially interact with mibolerone's androgenic activity. Supplements that might affect hepatic function were relevant considerations given the hepatotoxicity concerns with the drug. Regular monitoring throughout treatment allowed for detection of any unexpected effects that might suggest drug or supplement interactions.

General precautions for mibolerone use emphasized the importance of careful patient selection, thorough owner education about expected effects and potential side effects, and commitment to regular monitoring throughout treatment. The controlled substance status of mibolerone reflected its significant potential for adverse effects and required appropriate prescribing, dispensing, and record-keeping practices. Veterinary supervision was absolutely essential, and the drug should only have been used after thorough discussion of risks, benefits, and alternatives.

Breed-specific precautions were particularly important for mibolerone due to documented variations in drug metabolism and susceptibility to side effects. German Shepherds and German Shepherd mixes required higher doses for effective estrus suppression, typically receiving doses at the next higher weight category. Bedlington Terriers were contraindicated due to hereditary liver disease susceptibility. Other breeds with known predisposition to liver disorders required careful evaluation and potentially enhanced monitoring during treatment. Breed-specific dosing requirements emphasized the need for accurate breed identification and weight measurement.

Handling precautions for mibolerone required attention to human exposure risks, as androgenic steroids can affect human hormones. Pregnant women and women who might become pregnant should not have handled mibolerone, as transdermal absorption could occur and could potentially affect fetal development. Gloves were recommended when handling the medication, and care should have been taken to avoid spills or skin contact. The medication should have been stored securely to prevent accidental ingestion by children or pets.

Monitoring during mibolerone treatment included regular assessment for androgenic side effects, periodic liver function testing, and ongoing evaluation of the appropriateness of continued treatment. Baseline liver enzyme levels established before treatment provided comparison points for subsequent monitoring. Physical examination for clitoral enlargement, vulvar discharge, and other androgenic manifestations helped identify developing side effects. Behavioral changes should have been monitored and reported to the veterinarian. The decision to continue treatment was made on an ongoing basis, balancing the benefits of estrus suppression against the observed or potential side effects.

Special populations requiring additional consideration included dogs with any predisposition to liver disease, older dogs with declining hepatic function, and dogs receiving other medications affecting liver metabolism. Dogs with history of behavioral problems, particularly aggression, required careful evaluation before androgenic therapy was considered. The long-term implications of androgenic exposure for future breeding potential, though generally considered minimal if treatment duration was limited, deserved discussion with owners planning future breeding.

Mibolerone oral solution required storage according to manufacturer specifications, typically at controlled room temperature with protection from light and temperature extremes. The medication should have been kept in its original container with the child-resistant cap properly secured between uses. As a controlled substance, mibolerone required secure storage away from unauthorized access, with appropriate records maintained for regulatory compliance. The expiration date on the product should have been observed, and expired medication should not have been used.

Proper handling of mibolerone required attention to accurate dosing and human exposure prevention. The calibrated dropper provided with the product should have been used for all measurements to ensure consistent dosing. The dropper should have been kept clean and should not have contacted surfaces that could contaminate the medication. Hands should have been washed after handling the medication, and gloves were recommended for individuals regularly administering the drug. Care should have been taken to prevent spills, and any spilled medication should have been cleaned up carefully.

Disposal of mibolerone required attention to controlled substance regulations and environmental considerations. Unused medication should have been disposed of according to local regulations for controlled substances, which may have included take-back programs or specific disposal instructions. The medication should not have been discarded in regular household trash or flushed down drains without following appropriate disposal guidelines. Records of disposal may have been required for regulatory compliance given the controlled substance status. The veterinary clinic could have provided guidance on appropriate disposal methods and any required documentation.

Breed-specific considerations were particularly important for mibolerone due to documented variations in drug metabolism and contraindications that applied to specific breeds. Understanding these breed-related factors was essential for safe and effective use of the medication. Veterinarians considered breed identification carefully when evaluating whether mibolerone was appropriate for individual patients and when determining appropriate dosing.

German Shepherds and German Shepherd mixes required special dosing consideration because they appeared to metabolize mibolerone more rapidly than other breeds. Dogs of these breeds typically required doses at the next higher weight category to achieve effective estrus suppression. A German Shepherd weighing 60 pounds, for example, might have required the dose recommended for dogs over 100 pounds. This increased dose requirement was specifically noted in the product labeling and was essential for treatment success in affected breeds. Mixed breed dogs with German Shepherd heritage should have been evaluated for potential increased dose requirements.

Bedlington Terriers represented a breed-specific contraindication for mibolerone due to the hereditary copper storage hepatopathy that occurs in this breed. The liver disease predisposition in Bedlington Terriers made the hepatotoxic potential of mibolerone particularly concerning, and the drug was specifically contraindicated for this breed. Other breeds with known predisposition to liver disease, though not specifically contraindicated, required careful evaluation and potentially enhanced liver function monitoring during treatment.

Age considerations applied across all breeds and influenced the appropriateness of mibolerone treatment. The drug was indicated for adult dogs that had experienced at least one estrous cycle, as efficacy in prepubertal dogs was not established. Older dogs with declining liver function might have been at increased risk for hepatotoxicity and required careful evaluation. The maximum approved treatment duration of 24 months meant that the dog's age and expected future use (breeding, showing, etc.) should have been considered in treatment planning. Very young sexually mature dogs and senior dogs both warranted careful individual assessment before mibolerone was prescribed.

Within the category of hormonal agents for estrus control in dogs, several alternatives to mibolerone existed that utilized different mechanisms of action. Progestins such as medroxyprogesterone acetate and megestrol acetate were used for estrus suppression through different hormonal pathways, causing suppression of gonadotropins without the androgenic effects of mibolerone. However, progestins carried their own significant risks including increased likelihood of pyometra and mammary tumors. The GnRH agonist deslorelin (Suprelorin) provided reversible fertility suppression through pituitary desensitization, offering another alternative approach to managing reproduction in intact dogs.

Surgical ovariohysterectomy (spaying) remained the definitive and preferred method of permanent estrus prevention for dogs not intended for breeding. Unlike hormonal approaches, surgical sterilization eliminated the risks of pyometra, significantly reduced mammary tumor risk, and required no ongoing medication administration or monitoring. For most pet dogs, the advantages of surgical spaying clearly outweighed the temporary estrus suppression achieved with hormonal treatments. Hormonal approaches including mibolerone were reserved for specific situations where maintaining future breeding potential was important.

For dogs whose owners sought alternatives to hormonal estrus management, various management strategies existed for coping with estrus cycles without medical intervention. Careful containment during estrus, avoiding contact with intact males, and use of protective garments for discharge management allowed some owners to manage estrus naturally. These approaches required significant commitment and vigilance but avoided the side effects of hormonal therapy. Veterinary guidance helped owners understand all available options and make informed decisions about the most appropriate approach for their individual circumstances and goals.